SecBot SecBot
SECBOTREPLAY Home › Report › LRMR

LRMR · BLA submitted for nomlabofusp

Larimar Therapeutics, Inc. · 8-K filed Nov 9, 2026 at 16:08 ET

At the news

BULLISHIMPACT 7/10

8-K filed Nov 9, 2026 at 16:08 ET

Larimar Therapeutics completed its rolling BLA submission to the FDA seeking accelerated approval of nomlabofusp for Friedreich's ataxia, a major regulatory milestone for a clinical-stage biotech with a $245M market cap. The company also disclosed a preliminary cash balance of $128.7M as of September 30, 2026, down from $200.4M at March 31, 2026, with a projected cash runway into late Q2 2027.

  • Completed rolling BLA submission to FDA seeking accelerated approval of nomlabofusp for Friedreich's ataxia on November 9, 2026
  • FDA previously confirmed existing data package appears capable of supporting submission and review of a BLA seeking accelerated approval
  • FDA reaffirmed willingness to consider skin FXN as a novel surrogate endpoint
  • Preliminary cash, cash equivalents and marketable securities of $128.7M as of September 30, 2026, down from $200.4M at March 31, 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access